<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35457009</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>26</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>29</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1422-0067</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>23</Volume>
            <Issue>8</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Apr</Month>
              <Day>10</Day>
            </PubDate>
          </JournalIssue>
          <Title>International journal of molecular sciences</Title>
          <ISOAbbreviation>Int J Mol Sci</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Alzheimer's Disease and Tau Self-Assembly: In the Search of the Missing Link.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">4192</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms23084192</ELocationID>
        <Abstract>
          <AbstractText>Alzheimer's disease (AD) is a multifactorial neurodegenerative disease characterized by progressive cognitive impairment, apathy, and neuropsychiatric disorders. Two main pathological hallmarks have been described: neurofibrillary tangles, consisting of tau oligomers (hyperphosphorylated tau) and Aβ plaques. The influence of protein kinases and phosphatases on the hyperphosphorylation of tau is already known. Hyperphosphorylated tau undergoes conformational changes that promote its self-assembly. However, the process involving these mechanisms is yet to be elucidated. In vitro recombinant tau can be aggregated by the action of polyanions, such as heparin, arachidonic acid, and more recently, the action of polyphosphates. However, how that process occurs in vivo is yet to be understood. In this review, searching the most accurate and updated literature on the matter, we focus on the precise molecular events linking tau modifications, its misfolding and the initiation of its pathological self-assembly. Among these, we can identify challenges regarding tau phosphorylation, the link between tau heteroarylations and the onset of its self-assembly, as well as the possible metabolic pathways involving natural polyphosphates, that may play a role in tau self-assembly.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>González</LastName>
            <ForeName>Andrea</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Neurosciences and Functional Medicine, International Center for Biomedicine (ICC) and Faculty of Sciences, University of Chile, Santiago 7800020, Chile.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Singh</LastName>
            <ForeName>Sandeep Kumar</ForeName>
            <Initials>SK</Initials>
            <Identifier Source="ORCID">0000-0002-0022-6240</Identifier>
            <AffiliationInfo>
              <Affiliation>Indian Scientific Education and Technology Foundation, Lucknow 226002, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Churruca</LastName>
            <ForeName>Macarena</ForeName>
            <Initials>M</Initials>
            <Identifier Source="ORCID">0000-0002-1773-3652</Identifier>
            <AffiliationInfo>
              <Affiliation>Laboratory of Neurosciences and Functional Medicine, International Center for Biomedicine (ICC) and Faculty of Sciences, University of Chile, Santiago 7800020, Chile.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Maccioni</LastName>
            <ForeName>Ricardo B</ForeName>
            <Initials>RB</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Neurosciences and Functional Medicine, International Center for Biomedicine (ICC) and Faculty of Sciences, University of Chile, Santiago 7800020, Chile.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Faculty of Medicine, University of Chile, Santiago 7500922, Chile.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>04</Month>
          <Day>10</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Int J Mol Sci</MedlineTA>
        <NlmUniqueID>101092791</NlmUniqueID>
        <ISSNLinking>1422-0067</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011122">Polyphosphates</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016874" MajorTopicYN="N">Neurofibrillary Tangles</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011122" MajorTopicYN="N">Polyphosphates</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Alzheimer’s disease</Keyword>
        <Keyword MajorTopicYN="N">neurofibrillary tangles</Keyword>
        <Keyword MajorTopicYN="N">polyanions</Keyword>
        <Keyword MajorTopicYN="N">polyphosphates</Keyword>
        <Keyword MajorTopicYN="N">tau protein</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare no conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>8</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>30</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>31</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>23</Day>
          <Hour>1</Hour>
          <Minute>11</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35457009</ArticleId>
        <ArticleId IdType="pmc">PMC9032712</ArticleId>
        <ArticleId IdType="doi">10.3390/ijms23084192</ArticleId>
        <ArticleId IdType="pii">ijms23084192</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Morales I., Cerda-Troncoso C., Andrade V., Maccioni R.B. The Natural Product Curcumin as a Potential Coadjuvant in Alzheimer’s Treatment. J. Alzheimers Dis. 2017;60:451–460. doi: 10.3233/JAD-170354.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3233/JAD-170354</ArticleId>
            <ArticleId IdType="pubmed">28854504</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guzman-Martinez L., Maccioni R.B., Andrade V., Navarrete L.P., Pastor M.G., Ramos-Escobar N. Neuroinflammation as a Common Feature of Neurodegenerative Disorders. Front. Pharm. 2019;10:1008. doi: 10.3389/fphar.2019.01008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fphar.2019.01008</ArticleId>
            <ArticleId IdType="pmc">PMC6751310</ArticleId>
            <ArticleId IdType="pubmed">31572186</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hao K., Di Narzo A.F., Ho L., Luo W., Li S., Chen R., Li T., Dubner L., Pasinetti G.M. Shared genetic etiology underlying Alzheimer’s disease and type 2 diabetes. Mol. Asp. Med. 2015;43:66–76. doi: 10.1016/j.mam.2015.06.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.mam.2015.06.006</ArticleId>
            <ArticleId IdType="pmc">PMC6021176</ArticleId>
            <ArticleId IdType="pubmed">26116273</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matsuzaki T., Sasaki K., Tanizaki Y., Hata J., Fujimi K., Matsui Y., Sekita A., Suzuki S.O., Kanba S., Kiyohara Y., et al.  Insulin resistance is associated with the pathology of Alzheimer disease: The Hisayama study. Neurology. 2010;75:764–770. doi: 10.1212/WNL.0b013e3181eee25f.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0b013e3181eee25f</ArticleId>
            <ArticleId IdType="pubmed">20739649</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bedse G., Di Domenico F., Serviddio G., Cassano T. Aberrant insulin signaling in Alzheimer’s disease: Current knowledge. Front. Neurosci. 2015;9:204. doi: 10.3389/fnins.2015.00204.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fnins.2015.00204</ArticleId>
            <ArticleId IdType="pmc">PMC4468388</ArticleId>
            <ArticleId IdType="pubmed">26136647</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abolhassani N., Leon J., Sheng Z., Oka S., Hamasaki H., Iwaki T., Nakabeppu Y. Molecular pathophysiology of impaired glucose metabolism, mitochondrial dysfunction, and oxidative DNA damage in Alzheimer’s disease brain. Mech. Ageing Dev. 2017;161:95–104. doi: 10.1016/j.mad.2016.05.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.mad.2016.05.005</ArticleId>
            <ArticleId IdType="pubmed">27233446</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cortes N., Andrade V., Maccioni R.B. Behavioral and Neuropsychiatric Disorders in Alzheimer’s Disease. J. Alzheimers Dis. 2018;63:899–910. doi: 10.3233/JAD-180005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3233/JAD-180005</ArticleId>
            <ArticleId IdType="pubmed">29710717</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Donovan N.J., Locascio J.J., Marshall G.A., Gatchel J., Hanseeuw B.J., Rentz D.M., Johnson K.A., Sperling R.A., Harvard Aging Brain S. Longitudinal Association of Amyloid Beta and Anxious-Depressive Symptoms in Cognitively Normal Older Adults. Am. J. Psychiatry. 2018;175:530–537. doi: 10.1176/appi.ajp.2017.17040442.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1176/appi.ajp.2017.17040442</ArticleId>
            <ArticleId IdType="pmc">PMC5988933</ArticleId>
            <ArticleId IdType="pubmed">29325447</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ownby R.L., Crocco E., Acevedo A., John V., Loewenstein D. Depression and risk for Alzheimer disease: Systematic review, meta-analysis, and metaregression analysis. Arch. Gen. Psychiatry. 2006;63:530–538. doi: 10.1001/archpsyc.63.5.530.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/archpsyc.63.5.530</ArticleId>
            <ArticleId IdType="pmc">PMC3530614</ArticleId>
            <ArticleId IdType="pubmed">16651510</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Green R.C., Cupples L.A., Kurz A., Auerbach S., Go R., Sadovnick D., Duara R., Kukull W.A., Chui H., Edeki T., et al.  Depression as a risk factor for Alzheimer disease: The MIRAGE Study. Arch. Neurol. 2003;60:753–759. doi: 10.1001/archneur.60.5.753.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/archneur.60.5.753</ArticleId>
            <ArticleId IdType="pubmed">12756140</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Royall D.R., Palmer R.F. Alzheimer’s disease pathology does not mediate the association between depressive symptoms and subsequent cognitive decline. Alzheimers Dement. 2013;9:318–325. doi: 10.1016/j.jalz.2011.11.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jalz.2011.11.009</ArticleId>
            <ArticleId IdType="pmc">PMC4459124</ArticleId>
            <ArticleId IdType="pubmed">23154050</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chistyakov D.V., Astakhova A.A., Sergeeva M.G. Resolution of inflammation and mood disorders. Exp. Mol. Pathol. 2018;105:190–201. doi: 10.1016/j.yexmp.2018.08.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.yexmp.2018.08.002</ArticleId>
            <ArticleId IdType="pubmed">30098318</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Galts C.P.C., Bettio L.E.B., Jewett D.C., Yang C.C., Brocardo P.S., Rodrigues A.L.S., Thacker J.S., Gil-Mohapel J. Depression in neurodegenerative diseases: Common mechanisms and current treatment options. Neurosci. Biobehav. Rev. 2019;102:56–84. doi: 10.1016/j.neubiorev.2019.04.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neubiorev.2019.04.002</ArticleId>
            <ArticleId IdType="pubmed">30995512</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rojo L.E., Fernandez J.A., Maccioni A.A., Jimenez J.M., Maccioni R.B. Neuroinflammation: Implications for the pathogenesis and molecular diagnosis of Alzheimer’s disease. Arch. Med. Res. 2008;39:1–16. doi: 10.1016/j.arcmed.2007.10.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.arcmed.2007.10.001</ArticleId>
            <ArticleId IdType="pubmed">18067990</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maccioni R.B., Navarrete L.P., Gonzalez A., Gonzalez-Canacer A., Guzman-Martinez L., Cortes N. Inflammation: A Major Target for Compounds to Control Alzheimer’s Disease. J. Alzheimers Dis. 2020;76:1199–1213. doi: 10.3233/JAD-191014.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3233/JAD-191014</ArticleId>
            <ArticleId IdType="pubmed">32597798</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Canet G., Hernandez C., Zussy C., Chevallier N., Desrumaux C., Givalois L. Is AD a Stress-Related Disorder? Focus on the HPA Axis and Its Promising Therapeutic Targets. Front. Aging Neurosci. 2019;11:269. doi: 10.3389/fnagi.2019.00269.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fnagi.2019.00269</ArticleId>
            <ArticleId IdType="pmc">PMC6776918</ArticleId>
            <ArticleId IdType="pubmed">31611783</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morales I., Guzman-Martinez L., Cerda-Troncoso C., Farias G.A., Maccioni R.B. Neuroinflammation in the pathogenesis of Alzheimer’s disease. A rational framework for the search of novel therapeutic approaches. Front. Cell Neurosci. 2014;8:112. doi: 10.3389/fncel.2014.00112.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fncel.2014.00112</ArticleId>
            <ArticleId IdType="pmc">PMC4001039</ArticleId>
            <ArticleId IdType="pubmed">24795567</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tanzi R.E., McClatchey A.I., Lamperti E.D., Villa-Komaroff L., Gusella J.F., Neve R.L. Protease inhibitor domain encoded by an amyloid protein precursor mRNA associated with Alzheimer’s disease. Nature. 1988;331:528–530. doi: 10.1038/331528a0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/331528a0</ArticleId>
            <ArticleId IdType="pubmed">2893290</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grundke-Iqbal I., Iqbal K., Tung Y.C., Quinlan M., Wisniewski H.M., Binder L.I. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc. Natl. Acad. Sci. USA. 1986;83:4913–4917. doi: 10.1073/pnas.83.13.4913.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.83.13.4913</ArticleId>
            <ArticleId IdType="pmc">PMC323854</ArticleId>
            <ArticleId IdType="pubmed">3088567</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Muralidar S., Ambi S.V., Sekaran S., Thirumalai D., Palaniappan B. Role of tau protein in Alzheimer’s disease: The prime pathological player. Int. J. Biol. Macromol. 2020;163:1599–1617. doi: 10.1016/j.ijbiomac.2020.07.327.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ijbiomac.2020.07.327</ArticleId>
            <ArticleId IdType="pubmed">32784025</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shamsi A., Al Shahwan M., Ahamad S., Hassan M.I., Ahmad F., Islam A. Spectroscopic, calorimetric and molecular docking insight into the interaction of Alzheimer’s drug donepezil with human transferrin: Implications of Alzheimer’s drug. J. Biomol. Struct. Dyn. 2020;38:1094–1102. doi: 10.1080/07391102.2019.1595728.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/07391102.2019.1595728</ArticleId>
            <ArticleId IdType="pubmed">30898045</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fernandez J.A., Rojo L., Kuljis R.O., Maccioni R.B. The damage signals hypothesis of Alzheimer’s disease pathogenesis. J. Alzheimers Dis. 2008;14:329–333. doi: 10.3233/JAD-2008-14307.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3233/JAD-2008-14307</ArticleId>
            <ArticleId IdType="pubmed">18599959</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maccioni R.B., Rojo L.E., Fernandez J.A., Kuljis R.O. The role of neuroimmunomodulation in Alzheimer’s disease. Ann. NY Acad. Sci. 2009;1153:240–246. doi: 10.1111/j.1749-6632.2008.03972.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1749-6632.2008.03972.x</ArticleId>
            <ArticleId IdType="pubmed">19236346</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barres B.A. The mystery and magic of glia: A perspective on their roles in health and disease. Neuron. 2008;60:430–440. doi: 10.1016/j.neuron.2008.10.013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neuron.2008.10.013</ArticleId>
            <ArticleId IdType="pubmed">18995817</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li Q., Barres B.A. Microglia and macrophages in brain homeostasis and disease. Nat. Rev. Immunol. 2018;18:225–242. doi: 10.1038/nri.2017.125.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nri.2017.125</ArticleId>
            <ArticleId IdType="pubmed">29151590</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Serrano-Pozo A., Mielke M.L., Gomez-Isla T., Betensky R.A., Growdon J.H., Frosch M.P., Hyman B.T. Reactive glia not only associates with plaques but also parallels tangles in Alzheimer’s disease. Am. J. Pathol. 2011;179:1373–1384. doi: 10.1016/j.ajpath.2011.05.047.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ajpath.2011.05.047</ArticleId>
            <ArticleId IdType="pmc">PMC3157187</ArticleId>
            <ArticleId IdType="pubmed">21777559</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Henkel K., Karitzky J., Schmid M., Mader I., Glatting G., Unger J.W., Neumaier B., Ludolph A.C., Reske S.N., Landwehrmeyer G.B. Imaging of activated microglia with PET and [11C] PK 11195 in corticobasal degeneration. Mov. Disord. 2004;19:817–821. doi: 10.1002/mds.20040.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mds.20040</ArticleId>
            <ArticleId IdType="pubmed">15254941</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bolos M., Llorens-Martin M., Perea J.R., Jurado-Arjona J., Rabano A., Hernandez F., Avila J. Absence of CX3CR1 impairs the internalization of Tau by microglia. Mol. Neurodegener. 2017;12:1–14. doi: 10.1186/s13024-017-0200-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13024-017-0200-1</ArticleId>
            <ArticleId IdType="pmc">PMC5210310</ArticleId>
            <ArticleId IdType="pubmed">28049533</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morales I., Jimenez J.M., Mancilla M., Maccioni R.B. Tau oligomers and fibrils induce activation of microglial cells. J. Alzheimers Dis. 2013;37:849–856. doi: 10.3233/JAD-131843.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3233/JAD-131843</ArticleId>
            <ArticleId IdType="pubmed">23948931</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tang Y., Le W. Differential Roles of M1 and M2 Microglia in Neurodegenerative Diseases. Mol. Neurobiol. 2016;53:1181–1194. doi: 10.1007/s12035-014-9070-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12035-014-9070-5</ArticleId>
            <ArticleId IdType="pubmed">25598354</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Molofsky A.V., Krencik R., Ullian E.M., Tsai H.H., Deneen B., Richardson W.D., Barres B.A., Rowitch D.H. Astrocytes and disease: A neurodevelopmental perspective. Genes Dev. 2012;26:891–907. doi: 10.1101/gad.188326.112.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/gad.188326.112</ArticleId>
            <ArticleId IdType="pmc">PMC3347787</ArticleId>
            <ArticleId IdType="pubmed">22549954</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wan Y., Wang G., Chen S.D. Genetic predisposition to inflammation: A new risk factor of Alzheimer’s disease. Neurosci. Bull. 2008;24:314–322. doi: 10.1007/s12264-008-0619-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12264-008-0619-z</ArticleId>
            <ArticleId IdType="pmc">PMC5552535</ArticleId>
            <ArticleId IdType="pubmed">18839025</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liddelow S.A., Guttenplan K.A., Clarke L.E., Bennett F.C., Bohlen C.J., Schirmer L., Bennett M.L., Munch A.E., Chung W.S., Peterson T.C., et al.  Neurotoxic reactive astrocytes are induced by activated microglia. Nature. 2017;541:481–487. doi: 10.1038/nature21029.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature21029</ArticleId>
            <ArticleId IdType="pmc">PMC5404890</ArticleId>
            <ArticleId IdType="pubmed">28099414</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clarke L.E., Liddelow S.A., Chakraborty C., Munch A.E., Heiman M., Barres B.A. Normal aging induces A1-like astrocyte reactivity. Proc. Natl. Acad. Sci. USA. 2018;115:E1896–E1905. doi: 10.1073/pnas.1800165115.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1800165115</ArticleId>
            <ArticleId IdType="pmc">PMC5828643</ArticleId>
            <ArticleId IdType="pubmed">29437957</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu M., Dexheimer T., Sui D., Hovde S., Deng X., Kwok R., Bochar D.A., Kuo M.H. Hyperphosphorylated tau aggregation and cytotoxicity modulators screen identified prescription drugs linked to Alzheimer’s disease and cognitive functions. Sci. Rep. 2020;10:1–14. doi: 10.1038/s41598-020-73680-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41598-020-73680-2</ArticleId>
            <ArticleId IdType="pmc">PMC6959339</ArticleId>
            <ArticleId IdType="pubmed">31913322</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Neve R.L., Harris P., Kosik K.S., Kurnit D.M., Donlon T.A. Identification of cDNA clones for the human microtubule-associated protein tau and chromosomal localization of the genes for tau and microtubule-associated protein 2. Brain Res. 1986;387:271–280. doi: 10.1016/0169-328X(86)90033-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0169-328X(86)90033-1</ArticleId>
            <ArticleId IdType="pubmed">3103857</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schweers O., Schonbrunn-Hanebeck E., Marx A., Mandelkow E. Structural studies of tau protein and Alzheimer paired helical filaments show no evidence for beta-structure. J. Biol. Chem. 1994;269:24290–24297. doi: 10.1016/S0021-9258(19)51080-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0021-9258(19)51080-8</ArticleId>
            <ArticleId IdType="pubmed">7929085</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Luna-Viramontes N.I., Campa-Córdoba B.B., Ontiveros-Torres M.Á., Harrington C.R., Villanueva-Fierro I., Guadarrama-Ortíz P., Garcés-Ramírez L., de la Cruz F., Hernandes-Alejandro M., Martínez-Robles S., et al.  PHF-Core Tau as the Potential Initiating Event for Tau Pathology in Alzheimer’s Disease. Front. Cell Neurosci. 2020;14:247. doi: 10.3389/fncel.2020.00247.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fncel.2020.00247</ArticleId>
            <ArticleId IdType="pmc">PMC7511711</ArticleId>
            <ArticleId IdType="pubmed">33132840</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gong C.X., Liu F., Grundke-Iqbal I., Iqbal K. Post-translational modifications of tau protein in Alzheimer’s disease. J. Neural. Transm. Vienna. 2005;112:813–838. doi: 10.1007/s00702-004-0221-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00702-004-0221-0</ArticleId>
            <ArticleId IdType="pubmed">15517432</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maccioni R.B., Otth C., Concha I.I., Munoz J.P. The protein kinase Cdk5. Structural aspects, roles in neurogenesis and involvement in Alzheimer’s pathology. Eur. J. Biochem. 2001;268:1518–1527. doi: 10.1046/j.1432-1327.2001.02024.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1046/j.1432-1327.2001.02024.x</ArticleId>
            <ArticleId IdType="pubmed">11248668</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martin L., Latypova X., Terro F. Post-translational modifications of tau protein: Implications for Alzheimer’s disease. Neurochem. Int. 2011;58:458–471. doi: 10.1016/j.neuint.2010.12.023.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neuint.2010.12.023</ArticleId>
            <ArticleId IdType="pubmed">21215781</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alonso A.C., Grundke-Iqbal I., Iqbal K. Alzheimer’s disease hyperphosphorylated tau sequesters normal tau into tangles of filaments and disassembles microtubules. Nat. Med. 1996;2:783–787. doi: 10.1038/nm0796-783.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nm0796-783</ArticleId>
            <ArticleId IdType="pubmed">8673924</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gendron T.F., Petrucelli L. The role of tau in neurodegeneration. Mol. Neurodegener. 2009;4:1–19. doi: 10.1186/1750-1326-4-13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1750-1326-4-13</ArticleId>
            <ArticleId IdType="pmc">PMC2654562</ArticleId>
            <ArticleId IdType="pubmed">19126211</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gotz J., Halliday G., Nisbet R.M. Molecular Pathogenesis of the Tauopathies. Annu. Rev. Pathol. 2019;14:239–261. doi: 10.1146/annurev-pathmechdis-012418-012936.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1146/annurev-pathmechdis-012418-012936</ArticleId>
            <ArticleId IdType="pubmed">30355155</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bennecib M., Gong C.X., Grundke-Iqbal I., Iqbal K. Role of protein phosphatase-2A and -1 in the regulation of GSK-3, cdk5 and cdc2 and the phosphorylation of tau in rat forebrain. FEBS Lett. 2000;485:87–93. doi: 10.1016/S0014-5793(00)02203-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0014-5793(00)02203-1</ArticleId>
            <ArticleId IdType="pubmed">11086171</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun K.H., de Pablo Y., Vincent F., Shah K. Deregulated Cdk5 promotes oxidative stress and mitochondrial dysfunction. J. Neurochem. 2008;107:265–278. doi: 10.1111/j.1471-4159.2008.05616.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1471-4159.2008.05616.x</ArticleId>
            <ArticleId IdType="pubmed">18691386</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chung S.H. Aberrant phosphorylation in the pathogenesis of Alzheimer’s disease. BMB Rep. 2009;42:467–474. doi: 10.5483/BMBRep.2009.42.8.467.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5483/BMBRep.2009.42.8.467</ArticleId>
            <ArticleId IdType="pubmed">19712581</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dhavan R., Tsai L.H. A decade of CDK5. Nat. Rev. Mol. Cell Biol. 2001;2:749–759. doi: 10.1038/35096019.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/35096019</ArticleId>
            <ArticleId IdType="pubmed">11584302</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zambrano C.A., Egana J.T., Nunez M.T., Maccioni R.B., Gonzalez-Billault C. Oxidative stress promotes tau dephosphorylation in neuronal cells: The roles of cdk5 and PP1. Free Radic. Biol. Med. 2004;36:1393–1402. doi: 10.1016/j.freeradbiomed.2004.03.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.freeradbiomed.2004.03.007</ArticleId>
            <ArticleId IdType="pubmed">15135175</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takahashi M., Tsujioka Y., Yamada T., Tsuboi Y., Okada H., Yamamoto T., Liposits Z. Glycosylation of microtubule-associated protein tau in Alzheimer’s disease brain. Acta. Neuropathol. 1999;97:635–641. doi: 10.1007/s004010051040.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s004010051040</ArticleId>
            <ArticleId IdType="pubmed">10378383</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu F., Zaidi T., Iqbal K., Grundke-Iqbal I., Merkle R.K., Gong C.X. Role of glycosylation in hyperphosphorylation of tau in Alzheimer’s disease. FEBS Lett. 2002;512:101–106. doi: 10.1016/S0014-5793(02)02228-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0014-5793(02)02228-7</ArticleId>
            <ArticleId IdType="pubmed">11852060</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Planel E., Yasutake K., Fujita S.C., Ishiguro K. Inhibition of protein phosphatase 2A overrides tau protein kinase I/glycogen synthase kinase 3 beta and cyclin-dependent kinase 5 inhibition and results in tau hyperphosphorylation in the hippocampus of starved mouse. J. Biol. Chem. 2001;276:34298–34306. doi: 10.1074/jbc.M102780200.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M102780200</ArticleId>
            <ArticleId IdType="pubmed">11441005</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shamsi A., Anwar S., Mohammad T., Alajmi M.F., Hussain A., Rehman M.T., Hasan G.M., Islam A., Hassan M.I. MARK4 Inhibited by AChE Inhibitors, Donepezil and Rivastigmine Tartrate: Insights into Alzheimer’s Disease Therapy. Biomolecules. 2020;10:789.  doi: 10.3390/biom10050789.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/biom10050789</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Waseem R., Anwar S., Khan S., Shamsi A., Hassan M.I., Anjum F., Shafie A., Islam A., Yadav D.K. MAP/Microtubule Affinity Regulating Kinase 4 Inhibitory Potential of Irisin: A New Therapeutic Strategy to Combat Cancer and Alzheimer’s Disease. Int. J. Mol. Sci. 2021;22:10986.  doi: 10.3390/ijms222010986.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms222010986</ArticleId>
            <ArticleId IdType="pmc">PMC8537121</ArticleId>
            <ArticleId IdType="pubmed">34681645</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saint-Aubert L., Lemoine L., Chiotis K., Leuzy A., Rodriguez-Vieitez E., Nordberg A. Tau PET imaging: Present and future directions. Mol. Neurodegener. 2017;12:1–21. doi: 10.1186/s13024-017-0162-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13024-017-0162-3</ArticleId>
            <ArticleId IdType="pmc">PMC5210310</ArticleId>
            <ArticleId IdType="pubmed">28049533</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shi Y., Murzin A.G., Falcon B., Epstein A., Machin J., Tempest P., Newell K.L., Vidal R., Garringer H.J., Sahara N., et al.  Cryo-EM structures of tau filaments from Alzheimer’s disease with PET ligand APN-1607. Acta. Neuropathol. 2021;141:697–708. doi: 10.1007/s00401-021-02294-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00401-021-02294-3</ArticleId>
            <ArticleId IdType="pmc">PMC8043864</ArticleId>
            <ArticleId IdType="pubmed">33723967</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lomakin A., Chung D.S., Benedek G.B., Kirschner D.A., Teplow D.B. On the nucleation and growth of amyloid beta-protein fibrils: Detection of nuclei and quantitation of rate constants. Proc. Natl. Acad. Sci. USA. 1996;93:1125–1129. doi: 10.1073/pnas.93.3.1125.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.93.3.1125</ArticleId>
            <ArticleId IdType="pmc">PMC40042</ArticleId>
            <ArticleId IdType="pubmed">8577726</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Crowther R.A., Jakes R., Spillantini M.G., Goedert M. Synthetic filaments assembled from C-terminally truncated alpha-synuclein. FEBS Lett. 1998;436:309–312. doi: 10.1016/S0014-5793(98)01146-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0014-5793(98)01146-6</ArticleId>
            <ArticleId IdType="pubmed">9801138</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kuret J., Chirita C.N., Congdon E.E., Kannanayakal T., Li G., Necula M., Yin H., Zhong Q. Pathways of tau fibrillization. Biochim. Biophys. Acta. 2005;1739:167–178. doi: 10.1016/j.bbadis.2004.06.016.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbadis.2004.06.016</ArticleId>
            <ArticleId IdType="pubmed">15615636</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kampers T., Friedhoff P., Biernat J., Mandelkow E.M., Mandelkow E. RNA stimulates aggregation of microtubule-associated protein tau into Alzheimer-like paired helical filaments. FEBS Lett. 1996;399:344–349. doi: 10.1016/S0014-5793(96)01386-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0014-5793(96)01386-5</ArticleId>
            <ArticleId IdType="pubmed">8985176</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Perez M., Valpuesta J.M., Medina M., Montejo de Garcini E., Avila J. Polymerization of tau into filaments in the presence of heparin: The minimal sequence required for tau-tau interaction. J. Neurochem. 1996;67:1183–1190. doi: 10.1046/j.1471-4159.1996.67031183.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1046/j.1471-4159.1996.67031183.x</ArticleId>
            <ArticleId IdType="pubmed">8752125</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goedert M., Jakes R., Spillantini M.G., Hasegawa M., Smith M.J., Crowther R.A. Assembly of microtubule-associated protein tau into Alzheimer-like filaments induced by sulphated glycosaminoglycans. Nature. 1996;383:550–553. doi: 10.1038/383550a0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/383550a0</ArticleId>
            <ArticleId IdType="pubmed">8849730</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mukrasch M.D., Biernat J., von Bergen M., Griesinger C., Mandelkow E., Zweckstetter M. Sites of tau important for aggregation populate β-structure and bind to microtubules and polyanions. J. Biol. Chem. 2005;280:24978–24986. doi: 10.1074/jbc.M501565200.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M501565200</ArticleId>
            <ArticleId IdType="pubmed">15855160</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barghorn S., Mandelkow E. Toward a unified scheme for the aggregation of tau into Alzheimer paired helical filaments. Biochemistry. 2002;41:14885–14896. doi: 10.1021/bi026469j.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/bi026469j</ArticleId>
            <ArticleId IdType="pubmed">12475237</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chirita C.N., Necula M., Kuret J. Anionic micelles and vesicles induce tau fibrillization in vitro. J. Biol. Chem. 2003;278:25644–25650. doi: 10.1074/jbc.M301663200.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M301663200</ArticleId>
            <ArticleId IdType="pubmed">12730214</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chirita C.N., Kuret J. Evidence for an intermediate in tau filament formation. Biochemistry. 2004;43:1704–1714. doi: 10.1021/bi036034b.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/bi036034b</ArticleId>
            <ArticleId IdType="pubmed">14769048</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>King M.E., Ahuja V., Binder L.I., Kuret J. Ligand-dependent tau filament formation: Implications for Alzheimer’s disease progression. Biochemistry. 1999;38:14851–14859. doi: 10.1021/bi9911839.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/bi9911839</ArticleId>
            <ArticleId IdType="pubmed">10555967</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Friedhoff P., Schneider A., Mandelkow E.M., Mandelkow E. Rapid assembly of Alzheimer-like paired helical filaments from microtubule-associated protein tau monitored by fluorescence in solution. Biochemistry. 1998;37:10223–10230. doi: 10.1021/bi980537d.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/bi980537d</ArticleId>
            <ArticleId IdType="pubmed">9665729</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Makrides V., Shen T.E., Bhatia R., Smith B.L., Thimm J., Lal R., Feinstein S.C. Microtubule-dependent oligomerization of tau. Implications for physiological tau function and tauopathies. J. Biol. Chem. 2003;278:33298–33304. doi: 10.1074/jbc.M305207200.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M305207200</ArticleId>
            <ArticleId IdType="pubmed">12805366</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Von Bergen M., Barghorn S., Muller S.A., Pickhardt M., Biernat J., Mandelkow E.M., Davies P., Aebi U., Mandelkow E. The core of tau-paired helical filaments studied by scanning transmission electron microscopy and limited proteolysis. Biochemistry. 2006;45:6446–6457. doi: 10.1021/bi052530j.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/bi052530j</ArticleId>
            <ArticleId IdType="pubmed">16700555</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sahara N., Maeda S., Murayama M., Suzuki T., Dohmae N., Yen S.H., Takashima A. Assembly of two distinct dimers and higher-order oligomers from full-length tau. Eur. J. Neurosci. 2007;25:3020–3029. doi: 10.1111/j.1460-9568.2007.05555.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1460-9568.2007.05555.x</ArticleId>
            <ArticleId IdType="pubmed">17561815</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maeda S., Sahara N., Saito Y., Murayama M., Yoshiike Y., Kim H., Miyasaka T., Murayama S., Ikai A., Takashima A. Granular tau oligomers as intermediates of tau filaments. Biochemistry. 2007;46:3856–3861. doi: 10.1021/bi061359o.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/bi061359o</ArticleId>
            <ArticleId IdType="pubmed">17338548</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Binder L.I., Guillozet-Bongaarts A.L., Garcia-Sierra F., Berry R.W. Tau, tangles, and Alzheimer’s disease. Biochim. Biophys. Acta. 2005;1739:216–223. doi: 10.1016/j.bbadis.2004.08.014.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbadis.2004.08.014</ArticleId>
            <ArticleId IdType="pubmed">15615640</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abraha A., Ghoshal N., Gamblin T.C., Cryns V., Berry R.W., Kuret J., Binder L.I. C-terminal inhibition of tau assembly in vitro and in Alzheimer’s disease. J. Cell Sci. 2000;113:3737–3745. doi: 10.1242/jcs.113.21.3737.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1242/jcs.113.21.3737</ArticleId>
            <ArticleId IdType="pubmed">11034902</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shammas S.L., Garcia G.A., Kumar S., Kjaergaard M., Horrocks M.H., Shivji N., Mandelkow E., Knowles T.P., Mandelkow E., Klenerman D. A mechanistic model of tau amyloid aggregation based on direct observation of oligomers. Nat. Commun. 2015;6:1–10. doi: 10.1038/ncomms8025.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncomms8025</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wickramasinghe S.P., Lempart J., Merens H.E., Murphy J., Huettemann P., Jakob U., Rhoades E. Polyphosphate Initiates Tau Aggregation through Intra- and Intermolecular Scaffolding. Biophys. J. 2019;117:717–728. doi: 10.1016/j.bpj.2019.07.028.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bpj.2019.07.028</ArticleId>
            <ArticleId IdType="pmc">PMC6712485</ArticleId>
            <ArticleId IdType="pubmed">31400913</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Farooqui A.A., Horrocks L.A. Phospholipase A2-generated lipid mediators in the brain: The good, the bad, and the ugly. Neuroscientist. 2006;12:245–260. doi: 10.1177/1073858405285923.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1073858405285923</ArticleId>
            <ArticleId IdType="pubmed">16684969</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Diaz-Nido J., Wandosell F., Avila J. Glycosaminoglycans and beta-amyloid, prion and tau peptides in neurodegenerative diseases. Peptides. 2002;23:1323–1332. doi: 10.1016/S0196-9781(02)00068-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0196-9781(02)00068-2</ArticleId>
            <ArticleId IdType="pubmed">12128089</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Su J.H., Cummings B.J., Cotman C.W. Localization of heparan sulfate glycosaminoglycan and proteoglycan core protein in aged brain and Alzheimer’s disease. Neuroscience. 1992;51:801–813. doi: 10.1016/0306-4522(92)90521-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0306-4522(92)90521-3</ArticleId>
            <ArticleId IdType="pubmed">1488123</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kjellen L., Lindahl U. Proteoglycans: Structures and interactions. Annu. Rev. Biochem. 1991;60:443–475. doi: 10.1146/annurev.bi.60.070191.002303.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1146/annurev.bi.60.070191.002303</ArticleId>
            <ArticleId IdType="pubmed">1883201</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arrasate M., Perez M., Valpuesta J.M., Avila J. Role of glycosaminoglycans in determining the helicity of paired helical filaments. Am. J. Pathol. 1997;151:1115–1122.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1858049</ArticleId>
            <ArticleId IdType="pubmed">9327745</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arrasate M., Perez M., Armas-Portela R., Avila J. Polymerization of tau peptides into fibrillar structures. The effect of FTDP-17 mutations. FEBS Lett. 1999;446:199–202. doi: 10.1016/S0014-5793(99)00210-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0014-5793(99)00210-0</ArticleId>
            <ArticleId IdType="pubmed">10100642</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cheng Y., Bai F. The Association of Tau With Mitochondrial Dysfunction in Alzheimer’s Disease. Front. Neurosci. 2018;12:163. doi: 10.3389/fnins.2018.00163.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fnins.2018.00163</ArticleId>
            <ArticleId IdType="pmc">PMC5874499</ArticleId>
            <ArticleId IdType="pubmed">29623026</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alavi Naini S.M., Soussi-Yanicostas N. Tau Hyperphosphorylation and Oxidative Stress, a Critical Vicious Circle in Neurodegenerative Tauopathies? Oxid. Med. Cell Longev. 2015;2015:151979. doi: 10.1155/2015/151979.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2015/151979</ArticleId>
            <ArticleId IdType="pmc">PMC4630413</ArticleId>
            <ArticleId IdType="pubmed">26576216</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu Y., Liu F., Iqbal K., Grundke-Iqbal I., Gong C.X. Decreased glucose transporters correlate to abnormal hyperphosphorylation of tau in Alzheimer disease. FEBS Lett. 2008;582:359–364. doi: 10.1016/j.febslet.2007.12.035.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.febslet.2007.12.035</ArticleId>
            <ArticleId IdType="pmc">PMC2247364</ArticleId>
            <ArticleId IdType="pubmed">18174027</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Monaghan P., Metcalfe N.B., Torres R. Oxidative stress as a mediator of life history trade-offs: Mechanisms, measurements and interpretation. Ecol. Lett. 2009;12:75–92. doi: 10.1111/j.1461-0248.2008.01258.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1461-0248.2008.01258.x</ArticleId>
            <ArticleId IdType="pubmed">19016828</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Joshi A.U., Minhas P.S., Liddelow S.A., Haileselassie B., Andreasson K.I., Dorn G.W., 2nd, Mochly-Rosen D. Fragmented mitochondria released from microglia trigger A1 astrocytic response and propagate inflammatory neurodegeneration. Nat. Neurosci. 2019;22:1635–1648. doi: 10.1038/s41593-019-0486-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41593-019-0486-0</ArticleId>
            <ArticleId IdType="pmc">PMC6764589</ArticleId>
            <ArticleId IdType="pubmed">31551592</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Badimon A., Strasburger H.J., Ayata P., Chen X., Nair A., Ikegami A., Hwang P., Chan A.T., Graves S.M., Uweru J.O., et al.  Negative feedback control of neuronal activity by microglia. Nature. 2020;586:417–423. doi: 10.1038/s41586-020-2777-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41586-020-2777-8</ArticleId>
            <ArticleId IdType="pmc">PMC7577179</ArticleId>
            <ArticleId IdType="pubmed">32999463</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cortes N., Guzman-Martinez L., Andrade V., Gonzalez A., Maccioni R.B. CDK5: A Unique CDK and Its Multiple Roles in the Nervous System. J. Alzheimers Dis. 2019;68:843–855. doi: 10.3233/JAD-180792.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3233/JAD-180792</ArticleId>
            <ArticleId IdType="pubmed">30856110</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Braak H., Braak E. Demonstration of amyloid deposits and neurofibrillary changes in whole brain sections. Brain Pathol. 1991;1:213–216. doi: 10.1111/j.1750-3639.1991.tb00661.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1750-3639.1991.tb00661.x</ArticleId>
            <ArticleId IdType="pubmed">1669710</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mohamed N.V., Herrou T., Plouffe V., Piperno N., Leclerc N. Spreading of tau pathology in Alzheimer’s disease by cell-to-cell transmission. Eur. J. Neurosci. 2013;37:1939–1948. doi: 10.1111/ejn.12229.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/ejn.12229</ArticleId>
            <ArticleId IdType="pubmed">23773063</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clavaguera F., Bolmont T., Crowther R.A., Abramowski D., Frank S., Probst A., Fraser G., Stalder A.K., Beibel M., Staufenbiel M., et al.  Transmission and spreading of tauopathy in transgenic mouse brain. Nat. Cell Biol. 2009;11:909–913. doi: 10.1038/ncb1901.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncb1901</ArticleId>
            <ArticleId IdType="pmc">PMC2726961</ArticleId>
            <ArticleId IdType="pubmed">19503072</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
